K. Zaman

Discipline

Psychologie (5) Sociologie (1) Sciences de l'information et de la communication (1) Economies et finances (1)

Type de document

Articles (37) Recensions (10) Colloques et conférences (4) Mémoires, Thèses et HDR (1)

Co-auteur

Date

Source

Mot-clé

cancer (29) Cancer (29) Cancer (29) Breast (29) Patients (29) Patients (28) Treatment (25) thérapie (17) Therapeutics (17) Human beings (17) procès (14) Cancer--Patients (14) Chemotherapy (12) Chemotherapy (12) oncologie (10) Control (10) Oncology (10) survie (9) Methods (9) Survival (9) Management (9) Methods (9) maladie (8) maladie (8) toxicité (7) Article (7) Tumors (7) Grammar, Comparative and general--Article (7) Article (7) Older people (7)

Documents écrit par K. Zaman (42) | parle de K. Zaman (0)

Elevated liver function tests in a patient with breast cancer.
C. Neftel et al.
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
C. Bandiera et al. (3 janv. 2023)
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
U. Hasler-Strub et al.
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
P. Courlet et al. (21 juin 2022)
Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?]
N. Dris et al. (18 mai 2022)
Oncologie [2021 Oncology update]
M.L. Meyer et al. (2 févr. 2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Diabète secondaire aux nouvelles thérapies ciblées contre le cancer [New-onset diabetes and novel targeted therapies against cancer]
A. Zordan et al. (2 juin 2021)
Cancer du sein chez la femme en [Breast cancer during pregnancy]
M. Schnetz et al. (19 mai 2021)
Oncologie [2020 oncology update]
G. Dei Tos et al. (27 janv. 2021)
Communication des risques en santé : revue de littérature et recommandations pour la pratique clinique. [Risk communication in healthcare: literature review and recommendations for clinical practice]
K. Selby et al. (4 nov. 2020)
Oncological care organisation during COVID-19 outbreak.
C.E. Onesti et al.
Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials" (Galvano et al. J Bone Oncol 2019; 18:100252).
E. Gonzalez-Rodriguez et al.
Cancer du sein: perspectives de médecine intégrative [Breast cancer: perspectives from integrative medicine]
A. Stravodimou et al. (27 mai 2020)
The isolation of cancer survivors.
G. Danesi et al.
Oncologie [Advances in Oncology 2019]
A. Vernadou et al. (15 janv. 2020)
Oncologie [Advances in Oncology 2019]
A. Vernadou et al. (15 janv. 2020)
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
M. Jermini et al. (25 mars 2019)
Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.
M. Fiche et al.
La biopsie liquide, une nouvelle opportunité pour l’oncologie personnalisée [Liquid biopsy, a new opportunity for personalized oncology]
C. Astaras et al. (16 mai 2018)
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
P.G. Tsoutsou et al. (2018)
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
K.A. Phillips et al. (26 avr. 2016)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.
N. Guex et al. (2015)

next